New research shows promise for cannabis in fighting cancer

513 0

The ability of cannabis to reduce or eliminate cancer is verified by science

With hundreds of cannabinoids in its composition, cannabis is a mystery that, through research and studies, gets unveiled slowly. A new study focused on a couple of cannabinoids present in the plant, discovered properties to fight tumor cells present in human Gastrointestinal Cancer Cells (GCC). Maryland-based Cannabics Pharmaceuticals Inc. is presenting the results of research at its Israel facility, which studied cannabichromene (CBC) and cannabigerol (CBG) and their effects on these cancer cells. The outcome has been extremely positive.

These are only preliminary but, according to CTO and Co-Founder Dr. Eyal Ballan, it really takes the company one step closer to the original vision of personalizing these cannabinoid-based cancer treatments. Based on information shared by Ballan, gastrointestinal cancer is one of the main cancers responsible for cancer-related deaths worldwide. Leading this study was Dr. Yaakov Waksman, who clarifies that these results leaning towards certain cannabinoids are attributed to a correlation between the Topological Polar Surface Area of a cannabinoid and the ability to induce cancer activity. The study points to CBC and CBG for having higher rates of necrosis in human GCC cells, compared to other cannabinoids.

Cannabics already set a plan in motion to develop these treatments and it just announced this month a Memorandum of Understanding with RCK Medical Cannabis in Israel. The intention is to developed cannabis chemovars targeting specifically gastrointestinal cancer. “We are intrigued to be involved in strain development designed to target cancer biopsies,” says RCKMC Co-Founder and CTO Dr. Noam Chehanovsky. “We have a large variety of strains and nurturing expertise, which together with our proprietary breeding technologies, lead to a wide range of chemotypes to be examined by Cannabics.”